Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Cavaliere

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Therapeutic Advances in Medical Oncology|January 6, 2021
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trialFrancesca Simionato, Camilla Zecchetto, Valeria Merz, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
British Journal of Cancer|December 9, 2022
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2020
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemicSerena Zuliani, Ilaria Zampiva, Daniela Tregnago, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Therapeutic Advances in Medical Oncology|January 6, 2021
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trialFrancesca Simionato, Camilla Zecchetto, Valeria Merz, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
British Journal of Cancer|December 9, 2022
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2020
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemicSerena Zuliani, Ilaria Zampiva, Daniela Tregnago, et al.
Pageof 4